Home/Biosimilar Atlas/Companies/Epygen Biotech

Epygen Biotech

Biosimilar developer, India. 1 development product across 1 molecule: insulin human.

First approval in the Atlas: May 2021, Epygen Biotech Private (INN only), insulin human (CDSCO)
FDAproducts approved0
EMAproducts approved0
MHRAproducts approved0
PMDAproducts approved0
HCproducts approved0
CDSCOproducts approved1
EDEproducts registered0
Connections
1molecule1product1 of 7markets0candidates in trials6companies on the same molecules

Portfolio by market

MoleculeProductFDAEMAMHRAPMDAHCCDSCOEDEMarkets
Insulin humanEpygen human insulin·····May 2021·1/7

Month shown is the first approval or registration of that product in that market.

Companies on the same molecules

Developers whose portfolios overlap most with Epygen Biotech, by number of shared molecules. Overlap is the clearest sign of who competes with whom for the same tenders and licensing partners.

BaxterOne shared molecule: insulin human2 molecules in its portfolioBiocon BiologicsOne shared molecule: insulin human9 molecules in its portfolioCadila PharmaceuticalsOne shared molecule: insulin human2 molecules in its portfolioEris LifesciencesOne shared molecule: insulin human2 molecules in its portfolioGland PharmaOne shared molecule: insulin human1 molecule in its portfolioM.J. BiopharmOne shared molecule: insulin human2 molecules in its portfolio

Chronology

Compare Epygen Biotech with other developers on the comparison page.

Considering a partner, a licence or a new market for a biosimilar portfolio? EvySaif's regulatory strategy and value dossier work covers the regulatory and market-access side of that decision.

Planning your biosimilar strategy?

EvySaif can help assess your regulatory pathway, clinical evidence requirements and market-entry strategy across India, UAE and other target markets.

Talk to a biosimilar regulatory consultant
Data current to September 2026.